Progression Of LCZ696 And Other Drugs In Treatment Of Chronic Heart Failure

When cardiac systolic and/or diastolic dysfunction, the venous return to the heart can not be fully discharged, which leads to pulmonary circula tion and/or systemic circulation congestion and cause cardiac cycle dysfunction syndrome and possibly heart failure. Over the past few decades, the main drugs used to treat chronic heart failure were angiotensin converting enzyme inhibitor/ angiotensin II receptor blocker, beta blockers, and aldosterone antagonists. Recently a new type of drug, angiotensin receptor neprilysin inhibitor, which named LCZ696 has been introduced. It has a dual inhibition of the renin angiotensin aldosterone system and neprilysin. In this article, the existing of heart failure therapy is reviewed, focusing on LCZ696 related pharmacological action, mechanism and clinical effect. At the same time, the other drugs which are under clinical trials for heart failure being mentioned here.